Somatic Mutations and Immunotherapy

Tran, Eric

doi:10.1002/9781118684535.ch3

Cited by 2 publications

(1 citation statement)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TMGs may not equally express all the minigenes, because they may be influenced by their position in the three‐dimensional structure of the protein translated from TMG, 18 , 19 whereas long peptides elicit a weaker CD8+ T‐cell response compared with TMGs. 20 Moreover, APCs may also form new antigens constructed by parts of the nearby minigenes. Nowadays, the in silico assistance can reduce the formation of such artificial antigens.…”

Section: Identify Nrtsmentioning

confidence: 99%

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy

Zhu

Qian

et al. 2021

MedComm

View full text Add to dashboard Cite

Adoptive cellular immunotherapy harnessing the intrinsic immune system for precise treatment has exhibited preliminary success against malignant tumors. As one of the emerging roles in adoptive cellular immunotherapy, neoantigen‐reactive T cell (NRT) focuses on the antigens expressed only by tumor cells. It exclusively obliterates tumor and spares normal tissues, achieving more satisfying effects. However, the development of NRT immunotherapy remains in a relatively primitive stage. Current challenges include identification of NRTs and maintenance of adoptive cell efficacy in vivo. The possible side effects and other limitations of this treatment also hinder its application. Here, we present an overview of NRT immunotherapy and discuss the progress and challenges as well as the prospects in this promising field.

show abstract

Section: Identify Nrtsmentioning

confidence: 99%

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy

Zhu

Qian

et al. 2021

MedComm

View full text Add to dashboard Cite

show abstract

Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFNγ-Secreting T Cells

Izosimova

Yuzhakova

Skatova

et al. 2021

IJMS

View full text Add to dashboard Cite

Recent advances in cancer immunotherapy have great promise for the treatment of solid tumors. One of the key limiting factors that hamper the decoding of physiological responses to these therapies is the inability to distinguish between specific and nonspecific responses. The identification of tumor-specific lymphocytes is also the most challenging step in cancer cell therapies such as adoptive cell transfer and T cell receptor (TCR) cloning. Here, we have elaborated a protocol for the identification of tumor-specific T lymphocytes and the deciphering of their repertoires. B16 melanoma engraftment following anti-PD1 checkpoint therapy provides better antitumor immunity compared to repetitive immunization with heat-shocked tumor cells. We have also revealed that the most error-prone part of dendritic cell (DC) generation, i.e., their maturation step, can be omitted if DCs are cultured at a sufficiently high density. Using this optimized protocol, we have achieved a robust IFNγ response to B16F0 antigens, but only within CD4+ T helper cells. A comparison of the repertoires of IFNγ-positive and -negative cells shows a prominent enrichment of certain clones with putative tumor specificity among the IFNγ+ fraction. In summary, our optimized protocol and the data provided here will aid in the acquisition of broad statistical data and the creation of a meaningful database of B16-specific TCRs.

show abstract

Somatic Mutations and Immunotherapy

Cited by 2 publications

References 92 publications

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy

Neoantigen‐reactive T cell: An emerging role in adoptive cellular immunotherapy

Deciphering Repertoire of B16 Melanoma Reactive TCRs by Immunization, In Vitro Restimulation and Sequencing of IFNγ-Secreting T Cells

Contact Info

Product

Resources

About